Global Development Support

The globalization of the marketplace is also no exception in the life science industry. Many domestic pharmaceutical companies are focusing on acquiring foreign markets and expanding their sales overseas. In addition, the global mega-pharmas are also active in Japan as part of their global strategies in order to deliver foreign superior drugs into the Japanese market as quickly as possible.
The Asian region, including China and South Korea, is not only “the emerging marketplace” of the 21st century with its large population, but is also attracting attention in the area of drug development to be a stage for the next generation of clinical trials of the Europe-Japan-US tripolar structure, as an area where it is possible to conduct global standard clinical trials in compliance with ICH-GCP. In particular, “Asian clinical trials” based on alliances and cooperation with the East Asia region are an important issue which the industry and the regulatory authorities are addressing in order to eliminate the delays of new drug introduction into Japan, the so-called “drug lag”.
We at ACRONET support implementation of the Asian and global clinical trials for Japanese sponsors through our partnerships and networks with CROs in the Asian region (Taiwan, China, South Korea, etc.) while taking advantage of our long experience as an agent for European non-clinical CROs.

On the other hand, it is another consequence of the globalization to introduce foreign candidate materials into Japan, to conduct efficient clinical trials domestically, and to bring them to Japanese market subsequently. Particularly, conducting clinical development, manufacturing and marketing in Japan of European and American bio-ventures’ unique compounds and candidate materials is not only a business opportunity, but also an important element to fill “the unmet medical needs”. There we provide contract research services and consulting for efficient clinical development work utilizing our experience in a variety of fields including monitoring, data management, statistical analysis and medical writing.

In addition, ACRONET uses the global network of Itochu Corporation to develop superior CROs, technology service providers and IT vendors, etc. overseas, and provides them as services suitable to customers in the Japanese life-science marketplace.